# Ambrisentan in Single Ventricle

> **NCT02080637** · PHASE2 · COMPLETED · sponsor: **Kevin Hill** · enrollment: 16 (actual)

## Conditions studied

- Hypoplastic Left Heart Syndrome
- Hypoplastic Right-sided Heart Complex

## Interventions

- **DRUG:** Ambrisentan
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02080637
- **Lead sponsor:** Kevin Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-08-20
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02080637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02080637, "Ambrisentan in Single Ventricle". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02080637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*